%0 Journal Article %T Definitive Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil for Advanced Cervical Esophageal Cancer: A Medium-Term Outcome %J Asian Pacific Journal of Cancer Prevention %I West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. %Z 1513-7368 %A Okamoto, Hiroshi %A Taniyama, Yusuke %A Sato, Chiaki %A Fukutomi, Toshiaki %A Ozawa, Yohei %A Ando, Ryohei %A Takahashi, Kozue %A Akaishi, Ryujiro %A Horie, Yuta %A Shinozaki, Yasuharu %A Unno, Michiaki %A Kamei, Takashi %D 2022 %\ 02/01/2022 %V 23 %N 2 %P 495-499 %! Definitive Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil for Advanced Cervical Esophageal Cancer: A Medium-Term Outcome %K Squamous Cell Carcinoma %K Definitive chemoradiotherapy %K Docetaxel %K Cisplatin %K 5-fluorouracil %R 10.31557/APJCP.2022.23.2.495 %X Background: Definitive chemoradiotherapy (dCRT) is widely considered as a treatment option for cervical esophageal squamous cell carcinoma (ESCC) toward preserving the larynx. We have reported favorable outcomes, including the treatment response rate and short-term survival of dCRT concomitant with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for advanced cervical ESCC. The aim of this paper was to report the subsequent progress of the study. Methods: We assessed 18 patients with advanced (clinical stage II–IV, including T4b and/or M1 lymph node) cervical ESCC at our department who received DCF-RT as the first-line treatment between December 2010 and June 2020. Results: A total of 14 men and 4 women underwent the study regimen. The pretreatment clinical stage included stage II, stage III, stage IVA, and stage IVB cases (including 9 patients with T4b) [8 trachea and 2 thyroids] and 7 patients with the M1 lymph node. The complete response (CR) was achieved in 15 patients, stable disease in 2, and progressive disease in 1. Of 15 patients with CR, 7 experienced recurrence, and 8 had continued CR. Frequent cases of grade ≥3 adverse effects included leucopenia, neutropenia, febrile neutropenia, and pharyngeal pain. The 3-year overall survival rate, disease-free survival rate, and disease-specific survival rate were 44.2%, 47.7%, and 48.6%, respectively. Conclusion: DCF-RT for advanced cervical esophageal cancer could achieve a favorable prognosis with larynx preservation. Further observations are warranted to establish the long-term prognosis, late complications of radiotherapy, and the significance of salvage surgery. %U https://journal.waocp.org/article_89971_6a521e07bc8404b4abf1ad6399798a87.pdf